fact sheet

microcures

microcures

Transformative siRNA Therapeutic Platform for Cellular-Driven Tissue Repair & Regeneration

MicroCures Overview

- **Preclinical drug development company** with growing portfolio of siRNA therapeutics designed to significantly accelerate and improve the quality of tissue/nerve/organ repair and regeneration
- Currently focused on advancing programs to the clinic **in 3 high impact corneal, nerve, and dermal indications**

Novel Science

- **Dynamically harnesses microtubules** as a therapeutic target
- **Discovery of untapped core cellular regulatory mechanisms** in two target families: accelerator portfolio and decelerator portfolio
- **Accelerator technology combines siRNA with novel FL2 target**
- **Proven in vivo efficacy and extensive functionality data** for all 3 lead indications (please see reverse for data study summaries)

Progressive Development Pipeline



Robust IP Portfolio

- **Extensive patent portfolio** – both worldwide license from Albert Einstein College of Medicine & Internally Developed
- **13 issued & 37 pending** – composition, method, formulation
- Patent lives extend to **2041**

Partnership Opportunities

- **Capital efficient business model** focused on achieving near-term directionality/milestones AND creating longer term value optionality for MicroCures and our partners
- **Currently seeking additional capital and licensing partner(s)** to further accelerate 2+ programs to the clinic, continue to expand IP portfolio, and build out leadership execution team

at a glance

- Leader in the science of cell movement and its integral role in tissue repair/regeneration and disease progression
- Novel and validated MOA for predictably and transiently controlling innate cell movement
- Locally administered, non-systemic siRNA formulations consistently demonstrate faster and more complete healing & regeneration of multiple tissue types – with significant advantages versus current standards of care and systemic treatments
- Diverse pipeline of programs focused on both orphan pathways and large unmet need populations -- positioned to advance rapidly to clinical trials
- Robust patent portfolio provides both broad product/ platform protection and high-value licensing or co-development opportunities
- Capital efficient business development to-date, with substantial non-dilutive funding from multiple government agencies and collaborations

For non-confidential presentation and additional information please contact us at info@microcures.com

microcures

microcures

Study data

MicroCures Platform Summary

LEAD CANDIDATES FOR CLINIC

Accelerator Technology

- **Corneal** wound repair (NK+)
- **Neural regeneration**: ***PNS*** & CNS
- **Dermal** wound & burn repair
- **Cardiac** tissue repair
- **Pulmonary** fibrosis prevention
- **Solid tumor** cell therapy penetration

Additional potential Accelerator applications include: neurodegenerative disease/trauma repair; hair follicle regrowth

CONTROLLING CELL MIGRATION

- ✓ *Local/Topical*
- ✓ *Non-Systemic*
- ✓ *Transient*
- ✓ *Cells Retain Their Identity*

Decelerator Technology

- Inhibit fibrosis
- Anti-metastasis
- Block tumor angiogenesis

3 Leading Programs:

Neurotrophic Keratitis Treatment

- **Orphan degenerative disease** -- damage of trigeminal innervation
- **MCR-231 eye drop** accelerates regeneration of trigeminal neurons and repair of the cornea – **MULTIPLE therapeutic outcomes**
- **> 2-fold increase in rate and quality of corneal healing**
- **Potential label expansion** into dry eye (>16M US patients), diabetic keratopathy (~225M global patients), post-Lasik surgery complications



Cavernous Nerve Regeneration after Radical Prostatectomy

- **Cavernous nerves** (CN) run along the prostate to the corporal tissue and control erectile function -- they are often **damaged** during radical prostatectomy (RP) **leading to erectile dysfunction (ED)**
- **Nearly all patients experience some form of ED post-RP** due to CN damage -- for many, ED persists > 5 years post-surgery
- **MCR-420, a biodegradable hydrogel**, can be applied to the nerves during surgery -- in preclinical studies, MCR-420 **accelerated cavernous nerve regeneration** post severing, leading to significantly faster and more complete restoration of erectile function.



Electron micrographs of cross sections of transected and MCR-420 treated nerves show regenerated axons distal to transection site, comparable to uninjured nerves.

Burn/Excision Wound Repair

- **>600,000 burn wounds** are treated in the clinic annually in the United States alone; patients are at risk of infection without proper re-epithelialization of these wound(s).
- **MCR-111 is topically applied** to improve healing. Preclinical studies in rodent and pig demonstrate a greater than **2x improvement** in the **rate of wound closure** after treatment.
- MCR-111 treated wounds exhibit **improved quality of restored skin**, with the emergence of mature dermal collagen, hair follicles, nerves and sweat glands – and significantly less scarring.